Lacidipine oral
- Drugs List
- Therapeutic Indications
- Dosage
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Oral formulations of lacidipine.
Drugs List
Therapeutic Indications
Uses
Hypertension
Dosage
Treatment should be adapted to the individual response.
Adults
Initial dose 2mg once daily in the morning, increased if necessary after intervals of 3 to 4 weeks to 4mg daily, then to 6mg daily if necessary.
Doses greater than 6mg daily have not been shown to be significantly more effective.
Treatment may be continued indefinitely.
Patients with Hepatic Impairment
There may be an increased hypotensive effect in patients with hepatic impairment. Monitor these patients carefully and in severe cases consider a dose reduction.
Contraindications
Children under 18 years
Acute porphyria
Aortic stenosis
Breastfeeding
Cardiogenic shock
Galactosaemia
Pregnancy
Severe left ventricular failure
Unstable angina
Within 1 month of a myocardial infarction
Precautions and Warnings
Cardiac conduction defects
Congenital long QT syndrome
Glucose-galactose malabsorption syndrome
Hepatic impairment
Ischaemic heart disease
Lactose intolerance
Poor cardiac reserve
Advise ability to drive/operate machinery may be affected by side effects
Contains lactose
Monitor patients with hepatic impairment
Discontinue if cardiogenic shock develops
Discontinue if ischaemic pain occurs shortly after starting therapy
Advise patient to moderate alcohol intake during treatment
Grapefruit prod increase dihydropyridine Ca channel blocker bioavailability
Lacidipine has not been shown to be effective for the secondary prevention of myocardial infarction.
Lacidipine has not had safety or efficacy established in the treatment of malignant hypertension.
Lacidipine should be used with caution in patients with hepatic impairment because antihypertensive effect may be increased.
Pregnancy and Lactation
Pregnancy
Lacidipine is contraindicated during pregnancy.
The manufacturer does not recommend using lacidipine during pregnancy unless the potential benefits for the mother outweigh the adverse effects to the foetus or neonate. Animal studies have shown teratogenic effects. Human data is limited and as such a potential risk cannot be ruled out.
Lactation
Lacidipine is contraindicated during breastfeeding.
The manufacturer does not recommend breastfeeding whilst using lacidipine unless the potential benefits for the mother outweigh the adverse effects to the neonate. Animal data reports lacidipine maybe excreted in breast milk, however presence in human breast milk is unknown. Effects on exposed infants are unknown.
Side Effects
Abdominal discomfort
Aggravation of angina
Angioedema
Asthenia
Depression
Dizziness
Erythema
Flushing
Gastro-intestinal symptoms
Gingival hyperplasia
Headache
Hypotension
Increase in alkaline phosphatase
Muscular cramps
Nausea
Oedema
Palpitations
Polyuria
Pruritus
Rash
Syncope
Tachycardia
Tremor
Urticaria
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: January 2020
Reference Sources
Summary of Product Characteristics: Lacidipine 2mg Film-Coated Tablets. Dr. Reddy's Laboratories (UK) Ltd. Revised March 2019.
Summary of Product Characteristics: Lacidipine 4mg Film-Coated Tablets. Dr. Reddy's Laboratories (UK) Ltd. Revised March 2019.
Summary of Product Characteristics: Lacidipine 6mg Film-Coated Tablets. Dr. Reddy's Laboratories (UK) Ltd. Revised March 2019.
Summary of Product Characteristics: Lacidipine 2mg Film-Coated Tablets. Teva UK Ltd. Revised June 2015.
Summary of Product Characteristics: Lacidipine 4mg Film-Coated Tablets. Teva UK Ltd. Revised November 2019.
Summary of Product Characteristics: Molap 4mg Film-Coated Tablets. Rivopharm UK Ltd. Revised November 2016.
Summary of Product Characteristics: Motens Tablets 2mg. GlaxoSmithKline UK. Revised June 2016.
Summary of Product Characteristics: Motens Tablets 4mg. GlaxoSmithKline UK. Revised June 2016.
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 28 January 2020
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.